Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2022-09-07 Declaration of Voting R…
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports a 'Change of breakdown of voting rights' by a shareholder (UCB SA) crossing a threshold. This directly corresponds to the definition of a major shareholding notification, which in the provided schema is best matched by 'Major Shareholding Notification' (MRQ), as it details changes in significant ownership levels.
2022-09-07 English
DGAP-DD: Heidelberg Pharma AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: Heidelberg Pharma AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly matches the definition of Director's Dealing, which corresponds to the filing type code DIRS. The document details the name of the person (Dr. Birgit Kudlek), their position, the nature of the transaction (Acquisition of shares through exercise of subscription rights), price, volume, and date.
2022-09-06 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It reports changes in the percentage of voting rights held by a specific entity (Huadong Medicine Investment Holding (Hongkong) Limited) and its controlling persons, crossing specific thresholds (35.00%). This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). Although it is a regulatory announcement disseminated via DGAP, the specific content is about major holdings, making MRQ more precise than the general RNS fallback.
2022-09-06 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution' and specifically announces the 'Publication of total number of voting rights' following an 'Other capital measure' effective on September 2, 2022. This content directly relates to changes in the total number of shares/voting rights, which falls under capital structure changes or related regulatory disclosures. Given the options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit as it deals with the total number of voting rights resulting from a capital measure. It is not a general earnings release (ER), a proxy statement (PSI), or a director's dealing (DIRS).
2022-09-05 English
Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure." It explicitly details the successful placement of new shares, the gross issue proceeds generated (approximately EUR 80 million), and the resulting changes in share capital and shareholder structure. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, it fits the definition of a Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the capital measure itself.
2022-08-30 English
DGAP-DD: Heidelberg Pharma AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding transactions by a 'person closely associated' with a member of the administrative body (Prof. Christof Hettich). The structure follows standard regulatory disclosure formats for insider transactions, specifically detailing the person, the issuer, the financial instrument, and the nature of the transaction (transfer of subscription rights). This directly corresponds to the definition of Director's Dealing.
2022-08-23 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.